# US 2026/0000631 A1 · Synthetic retinoids for use in rar activation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0000631 A1
- Document ID: US20260000631A1
- Status: Published application
- Kind: A1
- Application number: 19/231,208
- Filed: 2025-06-06
- Published: 2026-01-01
- Earliest claimed: 2019-03-11
- Assignees: University of Durham
- Applicants: University of Durham
- Inventors: Andrew Whiting; David Chisholm; Iain Greig; Thabat Khatib; Peter McCaffery
- Web page: https://patentgrep.com/patent/US20260000631A1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 63/74: having unsaturation outside the aromatic rings
- C07C 65/26: containing rings other than six-membered aromatic rings
- C07C 65/28: having unsaturation outside the aromatic rings
- C07D 213/79: Acids; Esters
- C07D 213/80: in position 3
- C07D 233/96: having three double bonds between ring members or between ring members and non-ring members
- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 241/38: with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D 241/42: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C12Q 1/485: {involving kinase}
- G01N 33/5041: {involving analysis of members of signalling pathways}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/70567: Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to compounds of formula I: in which A1-A7 and R1 to R5 are defined herein, for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). The invention also relates to pharmaceutical compounds comprising such compounds, and related methods of treatment. In an aspect, the invention relates to a method of screening compounds for therapeutic potential in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). Aspects of the invention relate to novel compounds of formula I in which at least one of A1 to A3 is N or at least one of A4 is CR12 or A5 is CR13 in which R12/R13 is halogen.

## Claims

### Claim 1

A compound of formula I:
in which:
A1 is N or CR6;
A2 is N or CR7;
A3 is N or CR8;
R6 and R8, are each independently hydrogen, C1-C10 alkyl, F, Br or Cl;
R7 is independently hydrogen, C1-C10 alkyl, F, Br, Cl or —OCR9 in which R9 is H or C1-C6 alkyl;
R1 to R4 are each independently alkyl C1-C10 alkyl, or R1 and R2 and/or R3 and R4 join to form a 3-membered ring;
A4 is N or CR12;
A5 is N or CR13;
A6 is N or CR14;
A7 is N or CR15;
each R12 to R15 is independently H, halogen or haloalkyl C1-C10; and
R5 is —C(═O) R16 or —C(═O)OR16 in which R16 is C1-10 alkyl;
with the proviso that at least one of A1 to A7 is N or at least one of R12 to R15 is F, Cl or Br;
and isomers thereof;
in free or in salt form;
for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR).

### Claim 2 (depends on 1)

A compound as claimed in claim 1, wherein at least one of A1 to A3 is N.

### Claim 3 (depends on 1)

A compound as claimed in claim 1, wherein A1 and A3 are N.

### Claim 4

A compound as claimed in any preceding claim, wherein A2 is CR7.

### Claim 5 (depends on 4)

A compound as claimed in claim 4, where R7 is hydrogen.

### Claim 6

A compound as claimed in any preceding claim, wherein R5 is —COOH.

### Claim 7

A compound as claimed in any preceding claim, wherein at least one of A4, A5 or A6 is CF.

### Claim 8 (depends on 1)

A compound according to claim 1, which is selected from:

### Claim 9 (depends on 8)

A compound according to claim 8, which is selected from:

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A compound as claimed in any of claims 1 to 9, wherein the disease or condition which is alleviated by the activation of RAR is selected from Amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis (MS), Alzheimer's disease, early-stage Alzheimer's disease, intermediate-stage Alzheimer's disease, late-stage Alzheimer's disease, cognitive disorders, memory impairment, memory deficit, senile dementia, cognitive impairment, mild cognitive impairment, stroke, traumatic brain injury, epilepsy and spinal cord injury.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A compound of formula I as defined in any of claims 1 to 10, in the manufacture of a medicament for use in the treatment of a disease or condition which is alleviated by the activation of RAR.

### Claim 12

A method of treatment of a patient with a disease or condition which is alleviated by the activation of RAR, the method comprising administering to a patient a therapeutically effective amount of a compound of formula I, wherein formula I is as defined herein.

### Claim 13

A pharmaceutical composition comprising a compound of formula I as defined herein, optionally in conjunction with one or more pharmaceutically acceptable excipients, diluents or carriers, for use in the treatment of a disease or condition which is alleviated by the activation of RAR.

### Claim 14

A compound of formula I:
in which:
A1 is N or CR6;
A2 is N or CR7;
A3 is N or CR8;
R6 and R8, are each independently hydrogen, C1-C10 alkyl, F, Br or CI;
R7 is independently hydrogen, C1-C10 alkyl, F, Br, Cl or —OCR9 in which R9 is H or C1-C6 alkyl;
R1 to R4 are each independently alkyl C1-C10 alkyl, or R1 and R2 and/or R3 and R4 join to form a 3-membered ring;
A4 is N or CR12;
A5 is N or CR13;
A6 is N or CR14;
A7 is N or CR15,
each R12 to R15 is independently H, halogen or haloalkyl C1-C10; and
R5 is —C(═O) R16, or —C(═O)OR16 in which R16 is C1-10 alkyl;
with the proviso that at least one of A1 to A3 is N or at least one of A4 is CR12 or A5 is CR13 in which R12/R13 is halogen; and
isomers thereof;
in free or in salt form.

### Claim 15 (depends on 14)

A compound as claimed in claim 14 in which at least one of A1 to A3 is N or at least one of A4 is CR12 or A5 is CR13 in which R12/R13 is F.

### Claim 16 (depends on 14, 15)

A compound as claimed in claim 14 or claim 15 in which at least one of A1 to A3 is N.

### Claim 17 (depends on 14, 15, 16)

A compound as claimed in any of claims 14 to 16 in which A1 and A3 are both N.

### Claim 18

A method of screening compounds for therapeutic potential in the treatment of conditions or diseases which are alleviated by the activation of RAR, the method comprising:
performing an assay to determine the efficacy (Emax) of a compound in activating a RAR as an indicator of genomic activity;
performing an assay to determine the efficacy (Emax) of a compound as an indicator of non-genomic activity;
for each assay, comparing the Emax to a baseline value; and
selecting those compounds which have an Emax above the baseline value in both assays for further investigation.

### Claim 19 (depends on 18)

A method as claimed in claim 18, wherein the assay to determine the efficacy (Emax) of a compound as an indicator of non-genomic activity is a kinase phosphorylation assay.

### Claim 20 (depends on 19)

A method as claimed in claim 19, wherein the kinase phosphorylation assay is an ERK1/2 phosphorylation assay.
